肠道益生菌辅治支气管哮喘患儿的效果及其作用机制

doi:10.3969/j.issn.1006-6233.2023.04.014

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1253 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨肠道益生菌辅治支气管哮喘患儿的效果及其作用机制。方法: 将2019年1月至2022年1月我院收治的105例支气管哮喘患儿采用简单随机法分为常规组52例和益生菌组53例。常规组给予常规治疗,益生菌组在常规基础上给予肠道益生菌辅助治疗。检测两组治疗前后肠道菌群、免疫功能及痰嗜酸性粒细胞占比(EOS%)、整合素α4β1、αvβ6的差异,统计不良反应及6个月内急性发作次数。结果: 治疗前,两组肠道菌群比较,差异无统计学意义(P>0.05);治疗后,益生菌组双歧杆菌、乳酸杆菌较前升高,大肠杆菌较前下降,常规组肠道菌群与治疗前比较,差异无统计学意义(P>0.05);益生菌组双歧杆菌、乳酸杆菌、大肠杆菌治疗前后差值均较常规组大(P<0.05)。治疗前,两组痰EOS%、整合素α4β1、αvβ6及免疫功能比较,差异无统计学意义(P>0.05);治疗后,两组CD8⁺及痰EOS%、整合素α4β1、αvβ6较前下降,CD4 Anhui+、CD4⁺/CD8⁺较前升高(P<0.05);且益生菌组治疗前后差值均较常规组大(P<0.05)。益生菌组发生不良反应3例,发生率为5.66%,与常规组的不良反应率11.54%比较,差异无统计学意义(P>0.05)。随访6个月期间,益生菌组急性发作次数(0.41±0.16)次,明显低于常规组急性发作次数(0.87±0.23)次,差异有统计学意义(P<0.05)。结论: 肠道益生菌辅治支气管哮喘可提高患儿免疫功能,降低急性发作次数,可能机制与改善肠道菌群结构及降低痰EOS%、整合素α4β1、αvβ6的表达有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	马其波
	詹峰
	钟冲
	顾涛

关键词 ：肠道益生菌, 支气管哮喘, 肠道菌群

Abstract：Objective: To investigate the effect of enteric probiotics supplementation in children with bronchial asthma and its mechanism of action. Methods: A total of 105 children with bronchial asthma admitted to our hospital from January 2019 to January 2022 were randomly divided into routine group (52 cases) and probiotic group (53 cases). The routine group was given routine treatment, and the probiotic group was given intestinal probiotics adjuvant treatment on the basis of routine treatment. The two groups were detected the differences of intestinal flora, immune function and sputum eosinophil percentage (EOS%), integrin α4β1 and αvβ6 before and after treatment, and the adverse effects and the number of acute attacks within 6 months were counted. Results: Before treatment, there was no significant difference in intestinal flora between the two groups (P>0.05). After treatment, bifidobacterium and lactobacillus in probiotics group were higher than before, while Escherichia coli was lower. There was no statistical significance in intestinal flora in conventional group compared with before treatment (P>0.05). The difference values of bifidobacterium, lactobacillus and Escherichia coli before and after treatment in probiotic group were larger than those in conventional group (P<0.05). Before treatment, there were no significant differences in sputum EOS%, integrin α4β1, αvβ6 and immune function between the two groups (P>0.05). After treatment, CD8 Anhui+, EOS% of sputum, integrin α4β1, αvβ6 were decreased, and CD4 Anhui+, CD4 Anhui+/CD8 Anhui+ were increased in both groups (P<0.05). The difference before and after treatment in probiotic group was larger than that in conventional group (P<0.05). There were 3 cases of adverse reaction in probiotics group, the incidence was 5.66%, and the adverse reaction rate was not statistically significant compared with 11.54% in conventional group (P>0.05). During the 6-month follow-up, the number of acute attacks in the probiotic group (0.41±0.16) was significantly lower than that in the conventional group (0.87±0.23), and the difference was statistically significant (P<0.05). Conclusion: Intestinal probiotics in the adjuvant treatment of bronchial asthma can improve the immune function of children and reduce the number of acute attacks. The possible mechanism is related to improving the structure of intestinal flora and reducing the expression of EOS%, integrin α4β1 and αvβ6 in sputum.

Key words： Enteric probiotics Bronchial asthma Intestinal flora

基金资助:2022年度安徽省中医药传承创新科研项目,(编号:2022CCYB14)

通讯作者: 顾涛

引用本文:

马其波, 詹峰, 钟冲, 顾涛. 肠道益生菌辅治支气管哮喘患儿的效果及其作用机制[J]. 河北医学, 2023, 29(4): 595-600.
MA Qibo, ZHAN Feng, ZHONG Chong, et al. Effectiveness of Enteric Probiotic Supplementation in the Treatment of Children with Bronchial Asthma and Its Mechanism of Action. HeBei Med, 2023, 29(4): 595-600.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2023.04.014 或 http://www.hbyxzzs.cn/CN/Y2023/V29/I4/595

[1] 庞英,朱书瑶,江南静,等.支气管哮喘儿童身高发育情况及相关因素分析[J].临床肺科杂志,2022,27(5):686-690.
[2] 王秀华,刘肖君.布地奈德联合孟鲁司特钠治疗儿童支气管哮喘的疗效及对肿瘤坏死因子-α的影响[J].中国现代医生,2019,57(21):59-61.
[3] 田超,史强,王晓玲.益生菌防治儿童支气管哮喘的系统评价[J].儿科药学杂志,2020,26(6):15-19.
[4] 夏巧湘,卢小蕴,方锦平.益生菌联合布地奈德对支气管哮喘患儿的疗效及对外周血CD4⁺和CD8⁺细胞水平的影响[J].中国微生态学杂志,2022,34(4):451-454.
[5] 中华医学会儿科学分会呼吸学组,《中华儿科杂志》编辑委员会.儿童支气管哮喘诊断与防治指南(2016年版)[J].中华儿科杂志,2016,54(3):167-181.
[6] 任红玲,吴铭辉.儿童注意缺陷多动障碍与支气管哮喘的关系及影响因素分析[J].安徽医学,2022,43(2):199-203.
[7] Fischl Anna,Eckrich Jonas,Passlack Vanessa,et al.Comparison of bronchial and nasal allergen provocation in children and adolescents with bronchial asthma and house dust mite sensitization[J].Pediatric allergy and immunology:official publication of the European Society of Pediatric Allergy and Immunology,2020,31(2):143-149.
[8] 石山领,张晓宇.肠道菌群与支气管哮喘发病相关机制研究进展[J].中华实用诊断与治疗杂志,2021,35(2):200-202.
[9] 罗妍妍,陈青.益生菌辅治小儿哮喘及对S100β蛋白、TLR4与炎性免疫因子的影响[J].中华肺部疾病杂志(电子版),2021,14(5):608-610.
[10] 袁嘉禧.益生菌与儿童过敏性疾病的研究进展[J].国际儿科学杂志,2022,49(7):483-487.
[11] 周璇,葛灿侠,陈羽,等.小儿消积止咳口服液联合西药治疗儿童支气管哮喘临床效果的远期观察[J].世界中医药,2020,15(11):1611-1614.
[12] 何学佳,朱薇薇,毕玫荣.肠道菌群通过短链脂肪酸参与过敏性哮喘气道高反应机制研究进展[J].中国儿童保健杂志,2020,28(4):431-434.
[13] El Maghraby,Hanaa M,Ismail,et al.Interleukin 10-1082 G/A gene polymorphism and susceptibility to bronchial asthma in children:a single-center study[J].Journal of interferon and cytokine research:The official journal of the International Society for Interferon and Cytokine Research,2021,41(10):385-390.